2018 Volume 128 Issue 12 Pages 2645-2651
We have analyzed the clinical variety of 13 patients with bullous pemphigoid (BP) who developed BP after oral administration of DPP4i between December 2009 and April 2016. The mean age at inclusion in the case series was 76.3 years (64-96 years). Patients developed BP between 3 months and over 3 years after the introduction of DPP4i. Of the 13 patients, 10 were on vildagliptin. According to the prognosis, we classified them into 3 groups; good after stopping DPP4i (group G), poor after stopping DPP4i (group P), and continuous DPP4i administration (group C). Group G presented non-inflammatory skin lesions, and both anti-BP180NC16a (CLEIA) and anti- full-length BP180 antibodies were negative or weekly positive. Skin lesions and antibody titers in Group P varied according to the case. Only a few cases in Group C were refractory to conventional therapy.